Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Alzheimer's disease is the most common form of dementia and is the fourth leading cause of
death among people 65 years of age and older. The global prevalence of the disease will
increase significantly as the population ages, unless preventative treatments can be
identified and marketed. The present study seeks to evaluate AZD3480 (TC-1734) compared to an
approved medication (donepezil) shown to improve cognition and function in patients with
Alzheimer's disease.